Eprenetapopt Plus Azacitidine in TP53-Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Phase II Study by the Groupe Francophone des Myelodysplasies (GFM)

Cluzeau, T; Sebert, M; Rahme, R; Cuzzubbo, S; Lehmann-Che, J; Madelaine, I; Peterlin, P; Beve, B; Attalah, H; Chermat, F; Miekoutima, E; Rauzy, OB; Recher, C; Stamatoullas, A; Willems, L; Raffoux, E; Berthon, C; Quesnel, B; Loschi, M; Carpentier, AF; Sallman, DA; Komrokji, R; Walter-Petrich, A; Chevret, S; Ades, L; Fenaux, P

Fenaux, P (corresponding author), Paris Univ, Paris, France.; Fenaux, P (corresponding author), Hop St Louis, Assistance Publ Hop Paris, Serv Hematol Senior, 1 Ave Claude Vellefaux, F-75475 Paris, France.

JOURNAL OF CLINICAL ONCOLOGY, 2021; 39 (14): 1575

Abstract

PURPOSE TP53-mutated (TP53m) myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) have very poor outcome irrespective of the treatment rec......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索